Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

NCT07359040 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07359040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Recruiting
Start date
July 1, 2025
Completion date
October 30, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, neoadjuvant therapy, non-small cell lung cancer, pd-1 inhibitors